Clinical trials: Liraglutide
Kidney Failure, Chronic, Prediabetic State
The Effect of Liraglutide in Patients With Prediabetes and Kidney Failure
The present study will examine the effects of liraglutide treatment during 26 weeks on several cardiovascular risk factors in patients with prediabetes and end-stage renal disease (ESRD).
- Trial name
- LiRA2 (NCT02284230)
- Testing
- Liraglutide
- Where
- Denmark
- Sponsor
- Bo Feldt-Rasmussen
Diabetes Mellitus, Type 2, Hemodialysis
Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients
Diabetes is the second leading cause of end stage renal disease in France (22% in the 2016 REIN register). In hemodialysis, its prevalence is higher, between 30-40% depending on the study.
- Conditions
- Diabetes Mellitus, Type 2, Hemodialysis, Obese
- Trial name
- LIRADIAL (NCT04529278)
- Testing
- Liraglutide
- Where
- 4 sites in France
- Volunteers
- 18 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Diabetes, Diabetes Mellitus, Type 2
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
This trial is conducted in Africa, Asia, Europe and North America. The purpose of the trial is to investigate the effect of insulin degludec (IDeg) in combination with liraglutide (Lira) and metformin (at least 1500 mg daily or…
- Trial name
- NCT01664247
- Testing
- insulin degludec, liraglutide
- Where
- 132 sites in United States, Canada and 9 more
- Volunteers
- 346 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes
The purpose of the study is to compare the pharmacodynamic effects of lixisenatide (AVE0010), in comparison to liraglutide, as an add-on treatment to metformin, over a period of 4 weeks of treatment.
- Trial name
- NCT01175473
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Liraglutide
- Where
- 7 sites in Germany
- Volunteers
- 148 people
- Sponsor
- Sanofi
Pre Diabetes, Polycystic Ovary Syndrome
Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS
There is a growing need to develop pharmacologic interventions to improve metabolic function in women with polycystic ovary syndrome (PCOS).
- Conditions
- Pre Diabetes, Polycystic Ovary Syndrome, Obesity Android
- Trial name
- SAXAPCOS (NCT03480022)
- Testing
- Liraglutide Pen Injector [Saxenda]
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Woman's
Diabetes, Healthy
Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy Volunteers
This trial is conducted in Europe. The aim of this trial is to compare the exposure of liraglutide in young versus elderly healthy subjects.
- Trial name
- NCT01507337
- Testing
- liraglutide
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Polycystic Ovary Syndrome (PCOS), Overweight
The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS
Polycystic ovary syndrome (PCOS) is a health problem that affects one in 10 women of childbearing age, which is usually characterized by hormonal imbalance and metabolism problems such as hyperandrogenism and obesity.
- Conditions
- Polycystic Ovary Syndrome (PCOS), Overweight, Obesity
- Trial name
- NCT03151005
- Testing
- Metformin-GLP-1 Receptor Agonist, Metformin-Oral Contraceptive(OC)
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Xinqiao Hospital of Chongqing
Metabolism and Nutrition Disorder, Obesity
Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects
This trial is conducted in the United States of America (USA). The aim of the trial is to investigate safety, tolerability and pharmacokinetics (the exposure of the trial drug in the body) for single doses of NNC9204-0530 alone…
- Trial name
- NCT02235961
- Testing
- NNC9204-0530, liraglutide
- Where
- United States
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together
This trial is conducted in Europe, Oceania, Africa, Asia and South America. This trial is designed to show the effect of treatment with liraglutide when adding to existing metformin therapy and to compare it with the effects of…
- Trial name
- LEAD-2 (NCT00318461)
- Testing
- liraglutide, metformin, glimepiride
- Where
- 190 sites in Argentina, Australia and 18 more
- Volunteers
- 1,091 people
- Sponsor
- Novo Nordisk A/S
Fatty Liver, Nonalcoholic, Diabetes Mellitus, Type 2
Anti-diabetic Drugs and Fatty Liver Management
Type 2 DM is one of the major risk factors for development of non-alcoholic fatty liver disease. The pooled prevalence of fatty liver among diabetics is 54% (95% CI 45%-64%).
- Trial name
- NCT05041673
- Testing
- Metformin
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Alexandria University
Type 2 Diabetes, Overweight
Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes
The purpose of this research study is to learn about the effect of Liraglutide, (Victoza®), on the fat surrounding the heart.Excessive amount of the fat around the heart is common in people with type 2 diabetes and can be…
- Conditions
- Type 2 Diabetes, Overweight, Obesity
- Trial name
- NCT02014740
- Testing
- Liraglutide, Metformin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Miami
Type 1 Diabetes
Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes
This is the first prospective randomized double-blind placebo-controlled study to investigate the effect of a GLP-1 analog, specifically liraglutide, on blood glucose levels and variability in subjects with type 1 diabetes…
- Trial name
- NCT01722227
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University at Buffalo
Obesity
Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid
The aim of this study is to investigate the effect of the treatment with the GLP-1 Analogon Liraglutide on the lipid metabolism an inflammation in adipose tissue.
- Trial name
- NCT02417103
- Testing
- GLP-1 (Liraglutide)
- Where
- Germany
- Volunteers
- 2 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Obesity
The Effect of Liraglutide on Pancreatic Hormones and Its Size
Glucagon-like peptide-1 (GLP-1) is a gastrointestinal hormone used to treat type 2 diabetes and severe overweight (Liraglutide).The two pancreas enzymes: amylase and lipase are slightly elevated in GLP-1 treated compared with…
- Trial name
- LIRAP (NCT03520062)
- Testing
- Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml
- Where
- Denmark
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Nicolai Jacob Wewer Albrechtsen
Type 1 Diabetes Mellitus
Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes Subjects
Each subject will be allocated to 2 periods of 3 months of once daily dosing with either liraglutide (1.2 mg) or placebo treatment (in random sequence) as add on to usual intensive insulin treatment.
- Trial name
- NCT02408705
- Testing
- Liraglutide, Mixed Meal Tolerance Test with paracetamol
- Where
- Austria
- Volunteers
- 14 people
- Sponsor
- Medical University of Graz
Type 2 Diabetes
Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation
Type 2 diabetes is a chronic disease that has reached epidemic proportions. In order to improve our strategies for preventing and treating type 2 diabetes the investigators need to better understand the mechanism of this disease…
- Trial name
- NCT02198209
- Testing
- Liraglutide
- Where
- United States
- Sponsor
- Cedars-Sinai Medical Center
Healthy, Growth Hormone Deficiency
Effects of GH and Lirglutide on AgRP
This is a randomized, placebo-controlled, cross-over study with 4 arms. Healthy and GH deficient adults ages 18-45 years will be studied. Arms will consist of 21-day treatment periods and be separated by 8-week washout periods.
- Trial name
- NCT05681299
- Testing
- growth hormone and lirglutide, growth hormone, liraglutide
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Columbia University
Type 2 Diabetes
A Pharmacokinetic Study Comparing the Liraglutide Injection (RD12014) and Victoza® in Healthy Chinese Subjects
To evaluate the pharmacokinetics similarity between the liraglutide injection (RD12014) produced by Sunshine Lake Pharma Co., Ltd.
- Trial name
- NCT05294536
- Testing
- Liraglutide injection,RD12014, Liraglutide injection,Victoza
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Alzheimer's Disease
Evaluating Liraglutide in Alzheimer's Disease
This is a 12-month, multicentre randomised double-blind placebo-controlled Phase IIb study in patients with mild Alzheimer's dementia (AD). Patients will be randomised on a 1:1 ratio to receive liraglutide or matching placebo.
- Trial name
- ELAD (NCT01843075)
- Testing
- Liraglutide
- Where
- United Kingdom
- Volunteers
- 204 people
- Sponsor
- Imperial College London
Type-2 Diabetes
Liraglutide and Cardio-Metabolic Risk Markers
Incretin-based therapies have shown significant effects beyond those on glucose metabolism. We aim in the present study to evaluate the effects of liraglutide on several cardio-metabolic risk markers.
- Trial name
- NCT01715428
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- University of Palermo